lucira health is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. we produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.
Company profile
Ticker
LHDXQ
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DiAssess Inc.
SEC CIK
Corporate docs
IRS number
272491037
LHDXQ stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
4 Oct 23
8-K
Bankruptcy or Receivership
25 Sep 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jun 23
8-K
Other Events
12 Jun 23
NT 10-Q
Notice of late quarterly filing
16 May 23
8-K
Entry into a Material Definitive Agreement
24 Apr 23
8-K
Entry into a Material Definitive Agreement
18 Apr 23
NT 10-K
Notice of late annual filing
13 Apr 23
Transcripts
LHDXQ
Earnings call transcript
2022 Q3
15 Nov 22
LHDXQ
Earnings call transcript
2022 Q2
16 Aug 22
LHDXQ
Earnings call transcript
2022 Q1
13 May 22
LHDXQ
Earnings call transcript
2021 Q4
11 Mar 22
LHDXQ
Earnings call transcript
2021 Q3
12 Nov 21
LHDXQ
Earnings call transcript
2021 Q2
13 Aug 21
LHDXQ
Earnings call transcript
2021 Q1
14 May 21
Latest ownership filings
4
Erik T. Engelson
13 Mar 23
4
Richard Clavano Narido
13 Mar 23
4
Kevin Walter Collins
13 Mar 23
4
Anthony Joseph Allen
13 Mar 23
4
Ghazi Kashmolah
21 Feb 23
SC 13D/A
EPIQ Capital Group, LLC
22 Dec 22
4
Anthony Joseph Allen
22 Dec 22
4
Chad Boeding
16 Dec 22
4
Anthony Joseph Allen
9 Dec 22
4
Ghazi Kashmolah
9 Dec 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 41.72 mm | 41.72 mm | 41.72 mm | 41.72 mm | 41.72 mm | 41.72 mm |
Cash burn (monthly) | 11.73 mm | 6.68 mm | 42.28 mm | 11.91 mm | 9.41 mm | 6.86 mm |
Cash used (since last report) | 221.62 mm | 126.30 mm | 799.01 mm | 225.15 mm | 177.90 mm | 129.68 mm |
Cash remaining | -179.90 mm | -84.59 mm | -757.29 mm | -183.43 mm | -136.18 mm | -87.96 mm |
Runway (months of cash) | -15.3 | -12.7 | -17.9 | -15.4 | -14.5 | -12.8 |
Institutional ownership, Q1 2023
25.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 3 |
Closed positions | 24 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.44 bn |
Total shares | 10.51 mm |
Total puts | 0.00 |
Total calls | 12.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Eclipse Ventures | 6.22 mm | $1.43 bn |
Eclipse GP III | 4.18 mm | $0.00 |
Simplex Trading | 74.76 k | $17.00 k |
Resolute Advisors | 22.80 k | $5.24 mm |
BCS Barclays | 2.91 k | $1.00 k |
Clear Street | 1.00 k | $0.00 |
FNY Investment Advisers | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 23 | Kevin Walter Collins | Common Stock | Sell | Dispose S | No | No | 0.48 | 81,717 | 39.22 k | 234,903 |
7 Mar 23 | Richard Clavano Narido | Common Stock | Sell | Dispose S | No | No | 0.45 | 2,382 | 1.07 k | 77,910 |
6 Mar 23 | Richard Clavano Narido | Common Stock | Sell | Dispose S | No | No | 0.57 | 1,910 | 1.09 k | 80,292 |
3 Mar 23 | Erik T. Engelson | Common Stock | Sell | Dispose S | No | No | 1.09 | 60,000 | 65.40 k | 23,282 |
3 Mar 23 | Erik T. Engelson | Common Stock | Sell | Dispose S | No | No | 1.03 | 574,666 | 591.91 k | 83,282 |
3 Mar 23 | Erik T. Engelson | Common Stock | Option exercise | Acquire M | No | No | 0.82 | 574,666 | 471.23 k | 657,948 |
3 Mar 23 | Erik T. Engelson | Common Stock Common Stock | Option exercise | Dispose M | No | No | 0.82 | 574,666 | 471.23 k | 0 |
3 Mar 23 | Anthony Joseph Allen | Common Stock | Sell | Dispose S | No | No | 1 | 8,405 | 8.41 k | 136,520 |
3 Mar 23 | Kevin Walter Collins | Common Stock | Sell | Dispose S | No | No | 1.15 | 30,102 | 34.62 k | 316,620 |
3 Mar 23 | Richard Clavano Narido | Common Stock | Sell | Dispose S | No | No | 1 | 4,742 | 4.74 k | 82,202 |